Beta-lactam dose optimization in critical care is a current priority. We aimed to review the pharmacokinetics (PK) of three commonly used beta-lactams (amoxicillin ± clavulanate, piperacillin-tazobactam and meropenem) to compare PK parameters reported in critically and noncritically ill neonates, children and adults, and to investigate whether allometric and maturation scaling principles could be applied to describe changes in PK parameters through life.
Introduction
Infection is a common reason for admission to intensive care, accounting for 25-30% of admissions to adult units [1] [2] [3] and 8-12% of admissions to paediatric units [4, 5] . At any one time, half of the patients on an adult intensive care unit may be considered to have an infection [6] and up to 70% of intensive care patients will receive at least one course of antibiotics during their stay, regardless of age [6, 7] . Mortality for those with severe infection remains as high as 25-30% [5, 8] and infection remains one of the most common causes of death in neonates in the UK and worldwide [9] [10] [11] . Infection-associated healthcare costs are considerable, with pneumonia and septicaemia accounting for over $30 billion (approximately 8%) of US healthcare spending [12] .
The provision of prompt, targeted antimicrobial therapy is a key priority in the early stages of treatment of infection. While recent decades have seen the evolution of sepsis care bundles that tailor therapy for severe infection to the individual patient, antimicrobial dosing in critically ill patients remains largely identical to that in the noncritically ill [13] . This is despite the fact that pharmacokinetics (PK) in critical illness, particularly in patients at the extremes of the age spectrum, may be radically different from that in health or noncritical illness [14] .
In adults, antimicrobial PK in critical illness is increasingly an area of interest for researchers. Population approaches to PK data modelling have afforded the opportunity for the investigation of PK in specific patient groups, such as those with burns. However, studies are often small (n < 20) and reported PK parameters vary considerably. For example, Bourget et al. PK studies of antimicrobials in paediatric and neonatal populations are limited, with many dosing regimens still based on extrapolation from adults [17] . Anderson and Holford [18] argue that the scaling with size of the majority of biological systems can be described using an allometric power model with fixed exponents (e.g. 0.75 for clearance). This theory is supported by other work -e.g. by Calvier et al. [19] , who showed that 0.75 as a fixed scaling exponent provided a good explanation to the clearance of 12 620 hypothetical drugs in older children, with maturation meaning that this relationship breaks down with decreasing age. The age at which 0.75 scaling becomes inappropriate was found to be drug specific [19] . Holford et al. [20] separately argue that clearance maturation in intrauterine, neonatal and early life can be described by a sigmoidal (E max /Hill) function. Germovsek et al. [21] recently showed that combining these methods describes PK maturation well in neonates and children in a review of midazolam and gentamicin PK. Other examples of the success of this combined allometric and maturation approach include the busulfan model by McCune et al. [22] and a comparison of morphine models by Holford et al. [23] . One criticism of the focus on paediatric patients in these studies is that a common standard adult mature value is assumed, whereas we know that drug clearance declines with age [24] . To recommend beta-lactam dosing for patients of all ages, it would seem sensible to develop a model based on data from the whole population.
We therefore undertook a review of PK studies of three commonly used beta-lactam antibiotics: amoxicillin (± clavulanic acid), meropenem and piperacillin-tazobactam. Our aim was to compare the PK parameters reported in critically ill and noncritically ill neonates, children and adults, and to investigate whether allometric and maturation scaling principles could be applied to describe changes in PK parameters through life.
Methods

Data source and search strategy
The US national library of medicine PubMed search engine (including the MEDLINE database) and EMBASE electronic database (using the Wolters Kluwer OVID search engine) were used to search for human studies [25] [26] [27] . Drug name (e.g. 'amoxicillin') and 'pharmacokinetic*' were the key words searched for. Results were taken up to the 30th week of 2017. description of participant characteristics and the methods used for obtaining PK parameters, and included eight or more subjects (in order to exclude small case series or case reports).
Data extraction
We extracted the following data: number of participants, patient population and clinical setting, methods for estimating PK parameters and final structural model used (where compartmental methods were used), summary statistics of the age and weight of the study group, and PK parameters (clearance and volume of distribution). The 95% confidence intervals (CIs) for population mean values of PK parameters were recorded where published (including Bootstrap analyses) or were calculated, assuming a Student's t-distribution where standard deviation or standard error were published.
Scaling of parameters
PK parameters were scaled to 70 kg, using mean participant weight (or median where the mean was not published). Volume of distribution was scaled linearly with weight and clearance was scaled with an allometric exponent of 0.75, as described previously [18] (Equations 1). For parameters that were already allometrically scaled to 70 kg, the typical PK values were used directly from the source paper. Where V and CL are volume of distribution and clearance values identified from the study scaled to a 70 kg individual using the mean weight from the study participants (median used where the mean was not presented).
Data summary measures
Population mean/median PK parameters with CIs were plotted and compared in different populations using analysis of variance, where appropriate (adults/children/neonates, healthy/critically ill). Where comparisons between study groups were made (e.g. adult healthy and adult critically ill), unweighted mean parameter values were used. Unweighted means were used to avoid overinfluence of one or two larger studies in specific populations groups -e.g. the Udy et al. study (n = 48) of piperacillin in patients with augmented renal clearance [28] . Neonates were less than 28 days' corrected age, children were 28 days' corrected age to 18 years and adults were aged over 18. Where corrected, age in prematurely delivered neonates is chronological age from birth minus the number of days of prematurity. Prematurity is defined as birth earlier than 36 weeks' gestation.
Modelling the maturation-decline of PK through life 
Results
Study selection
A flowchart of study selection for each drug is provided in Figure 1 . A total of 2082 articles were identified and screened, with 130 studies included in the final analysis [15, 16, 28, . Some studies provided PK parameters for two drugs (e.g. piperacillin and tazobactam) or several discrete groups (e.g. 0-1, 1-2 years etc.), meaning that 173 sets of PK parameters were available for analysis. A summary of the articles identified, the patient setting, the number of participants and scaled PK parameters with calculated confidence intervals is presented in Appendix 1. The range of methods used to calculate PK parameters included noncompartmental analyses and population approaches using parametric and nonparametric methodology. 
PK parameters
Maturation-decline functions
Parameters for the maturation-decline function for each drug are shown in Table 2 . These were estimated using NONMEM from the PK parameters identified in the literature review. One study by Cohen-Wolkowiez et al. [132] was excluded from the piperacillin model fit as it used a scavenged sampling technique and the parameter estimates from this study were distinctly different from others in similar participants, and uncertainty was large. Two ceftolozanetazobactam studies [134, 135] were excluded from the tazobactam model fit as the clearance values from these studies deviated significantly from similar studies with piperacillin-tazobactam. Clavulanic acid was not modelled as the number of studies was small.
The pooled maturation model suggests that sizestandardized clearance approaches adult values at around 2 years postmenstrual age. Figure 4 shows a visual predictive check of the pooled model; it appears to describe age-related changes at the extremes of life well. As the amoxicillin data suggested higher volume of distribution in neonates, a 'hockey stick' function was fitted to these data ( Figure 5) , with a pivot point at 34 years [relative standard error (RSE) 29%].
Discussion
We have, for the first time, presented a unified model to describe beta-lactam PK throughout life. This was achieved by describing the changes in beta-lactam PK in early life using the standard allometric scaling and organ maturation functions described by Holford et al. [20] and further extending this model by using a sigmoidal decline function to describe the decline in clearance associated with old age. Parameters from the pooled model suggest that adult values of clearance are achieved at approximately 2 years postmenstrual age, and at 87 years beta-lactam clearance is half of that found in young adults. This quantification of the effect of age on beta-lactam PK could be used in dose-optimization studies.
The final parameter estimates for clearance maturation using pooled data were similar to values identified by Germovsek et al. [21] in their pooled analysis of gentamicin studies. These values are compared, along with the values suggested by Rhodin et al. [159] in their model of glomerular filtration maturation in Table 3 , noting that these betalactams undergo tubular secretion alongside filtration.
It is worth noting that Germovsek et al.
[21], in common with other similar studies that estimate maturation, excluded results from older adults to avoid the confounding effects of Figure 1 Flow diagram of studies identified in the review of antimicrobial pharmacokinetics (PK) age and the natural decline in renal function. In our analysis, we successfully described this decline using a sigmoidal function that mirrored that used to describe maturation. We used age as the covariate. It was not possible to use glomerular filtration to see if it explained all of the age effect, as studies were not consistent in the reporting of renal function. Some did not report it at all, some reported plasma creatinine, and those that did report glomerular filtration used a variety of methods. It is likely that there will remain some age effect, even after taking filtration into account, as active excretion plays a part in the elimination of these drugs. A further related limitation is that, for similar reasons, no account was taken in our model for studies that did include a creatinine clearance function in their clearance models. The AGE 50 parameter associated with a decline in clearance with age was similar for amoxicillin and piperacillin at 79 years and 74.8 years, respectively (Table 2 ). The value of 31.3 years for meropenem suggests that the model may have been skewed by one higher clearance value in children from the study by Pettit et al. [79] . The use of a decline function such as this therefore has merit as part of efforts toward dose optimization for all age groups, although investigating the validity of the decline function presented here requires pooled data across age groups with a consistent method of measuring renal function.
When comparing clearance parameters across these populations, it is perhaps interesting to note that mean clearance parameters were similar between critically and noncritically ill individuals ( 
Figure 3
Weight-standardized volume of distribution values identified from the literature search, plotted against age. Mean volume values (standardized to a 70-kg individual) from each study are plotted with an associated confidence interval (where available). The size of the points is proportional to the number of participants. Colours are used to denote the setting of the study. There appears to be greater uncertainty in parameter estimates of studies in critically ill compared with healthy populations. Weight-based allometric scaling appears to control for the effects of age, except for amoxicillin, where there appears to be a greater volume of distribution for neonates compared with adults
Figure 2
Weight-standardized clearance values identified from the literature search, plotted against age. The mean clearance values (standardized to a 70-kg individual) from each study are plotted with an associated confidence interval (where available). The size of the points is proportional to the number of participants. Colours are used to denote the setting of the study. There appears to be greater uncertainty in parameter estimates of studies in critically ill compared with healthy populations. As expected, there is a lower clearance in neonates and elderly populations, despite standardizing values allometrically mean clearance values in critically ill populations are similar to those in healthy populations. We think it is important to note that the CIs for the estimates of clearance were greater in critical illness studies compared with healthy volunteer studies, and suggest that this may indicate greater PK variability between critically ill individuals. Alternatively, this could be explained by greater systematic experimental error in critically ill studies. However, the observation arises from multiple studies (e.g. 25 critically ill and seven healthy volunteer datasets for piperacillin), and CIs for clearance in critically ill studies were also greater than in hospital inpatient studies (Appendix 1 and Figure 2 ), where the same systematic experimental errors would reasonably be expected. In addition, the number of participants (n) was greater in critically ill studies (piperacillin mean n of 26 in critically ill individuals vs. 13 in healthy volunteers), which one would ordinarily anticipate leading to greater certainty in parameter estimates. Increased PK variability might be clinically significant for drugs with concentrationtime-dependent killing. For example, the 95% CI for piperacillin clearance in the study by Shikuma et al. [89] had an almost threefold difference between lower and upper bounds 
Where: CL is the model predicted clearance; CL STD is a standardized clearance; PMA is the postmenstrual age in weeks and PMA 50 is the PMA age at which 50% of adult function is achieved; AGE is the age in years and AGE 50 is the AGE at which 50% of decline has occurred; θs are Hill coefficients. σ 2 is the estimated variance of ε. Data presented above are mean parameter estimates (% relative standard error)
Figure 4
Visual predictive check of maturation-decline model for clearance using pooled data from amoxicillin, piperacillin, meropenem and tazobactam. The shaded area is the interval between the 2.5th and 97.5th centiles of clearance values, simulated using the maturation-decline function (solid black line). Simulations from the model encapsulate literature clearance values (coloured dots) relatively well, although some sit below the lower confidence level
tional study of beta-lactams, reported that 16% of patients failed to achieve PK-pharmacodynamic targets, and that this was associated with treatment failure [163] . It was also interesting to note that the clearance values identified in the literature review for healthy individuals are lower than those published in the summary of product characteristics (Table 1) . For example, the mean weight-adjusted clearance for amoxicillin identified in healthy volunteer studies was 13.5 l h -1 70 kg
, compared with 25 l h -1 published in the summary of product characteristics [164] . It is not immediately clear why this should be the case. It may be that the summary of product characteristic values arise from unpublished data.
Changes in volume status are common in septic patients. Altered vascular tone and endothelial dysfunction lead to shifts in the distribution of fluid from the vascular to extravascular space [165] . This is reflected in the significantly greater volume of distribution described in the patient groups who are likely to be the most unwell (critically ill patients receiving piperacillin-tazobactam and meropenem). The variability in volume of distribution was also marked in critical illness studies. ). This wide variation was all the more remarkable, given that this was a relatively large study, including 50 participants. The relatively larger volume of distribution of amoxicillin in neonates compared with adults reflects recognized physiological differences in this age group [20], and Eleveld et al. [166, 167] recently described similar volume of distribution changes for remifentanil and propofol. The absence of such an effect in meropenem and piperacillin is probably explained by the fact that adult distributions of body water are reached relatively early in life, and there were no studies of these drugs in the very young. Indeed, the pivot point of 34 years in the amoxicillin volume of distribution model is much later than one might expect. This probably reflects a lack of data in young children and adolescents to inform the pivot point in this empirical model fit.
The greatest limitation of the maturation-decline functions described is the degree of uncertainty associated with the parameter estimates. For example, the postmenstrual age at which 50% of adult function is achieved (PMA 50 ) varied from 49 weeks to 398 weeks between drugs, with the large uncertainty for meropenem and tazobactam (relative standard error 236% and 151%, respectively), probably 
PMA is the postmenstrual age in weeks and PMA 50 is the PMA age at which 50% of adult function is achieved. θ 1 is the Hill parameter. PMA 50 and θ 1 are estimated in the model fitting process.
Figure 5
Visual predictive check of amoxicillin volume of distribution values using the 'hockey-stick' function. Shaded area is the interval between 2.5th and 97.5th centiles of amoxicillin volume of distribution values, simulated using the hockey-stick function (dashed line)
reflecting the lack of data in young children. These estimates are derived from what are, in general, small PK studies, with a median of 14 participants. Furthermore, the uncertainty of PK parameter estimates from these studies was not taken into account in the estimation of the parameters of the maturation-decline function. By using only mean (or median) values, information is clearly lost and each study contributes identically to the model fit, regardless of size of the study or uncertainty reported. However, it is worth noting that the median number of participants was similar across drugs (Table 1) , and weighting for sample size might have led to overinfluence of larger studies in specific patient groups -e.g. Jeon et al.
[16] n = 50 burns patients. Similarly, requesting raw data was impractical and unlikely to yield a significant response in the limited time available for the present study. Indeed, Germovsek et al. [168] , in their review of gentamicin, obtained data from only two of eight authors. Such a low response rate was felt unlikely to improve the inferences that can be made from this retrospective review -particularly as some of the research dates back to the mid-20th century, further decreasing the potential for obtaining raw data. A prospective age-inclusive PK study could improve the accuracy of the parameter estimates.
Conclusions
Over the past decade, a standardized method has been developed to handle the maturation of clearance throughout childhood. Much less work has been undertaken to describe the effect of ageing on clearance, limiting the potential to fit models across all age groups. Antimicrobial resistance and high sepsis-related mortality is a problem for patients of any age. The beta-lactam model presented here could be used for dose optimization throughout life, although a prospective study to evaluate our model is warranted. We also foresee a number of other potential uses for our model by others. For example, for those conducting focused PK studies with narrow age ranges, the size and maturation parameters in our model could be fixed, thereby allowing for the exploration of other covariates after size and age are delineated. The parameters could potentially assist with the conduct of in vitro hollow-fibre experiments seeking to mimic human concentration-time profiles in specific age groups. For secondary analysis of clinical trials where no PK are collected, our parameters could be used to predict typical exposure for given dose schemes.
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